Advanced glycation end products in intervertebral discs and hip joint capsules: Correlation with senile amyloid?

Amyloid

Volumn 12, Issue 3, 2005, Pages 167-173

  Foitschik, Tina ^a   Saeger, Wolfgang ^a,c   Riebe, Mona ^b   Röcken, Christoph ^b  

^a Institute of Pathology   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Advanced glycation end products; Amyloid; Hip joint capsule; Immunohistology; Intervertebral disc

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID;

AGED; AMYLOIDOSIS; ARTICLE; CORRELATION ANALYSIS; FEMALE; HIP; HUMAN; IMMUNOHISTOCHEMISTRY; INTERVERTEBRAL DISK; JOINT CAPSULE; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID; AMYLOIDOSIS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HIP JOINT; HUMANS; INTERVERTEBRAL DISK; JOINT CAPSULE; MALE; MIDDLE AGED;

EID: 27144534285     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120500222094     Document Type: Article

References (46)

1. Saeger W, Urban P. Tendosynovial amyloid: classification and correlation. Path Res Prac 2002;198:249 (Abstr. 410).
2. Selkoe DJ. Normal and abnormal biology of the β-amyloid precursor protein. Ann Rev Neurosci 1994;17:489-517.
3. Fraser PE, Lévesque L, McLachlan DR. Biochemistry of Alzheimer's disease amyloid plaques. Clin Biochem 1993; 26:339-349.
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
5. Verbeek MM, Ruiter DJ, de Waal RMW. The role of amyloid in the pathogenesis of Alzheimer's disease. Biol Chem 1997; 378:937-950.
6. Johnson KH, O'Brien TD, Betsholtz C, Westermark P. Islet amyloid polypeptide: mechanisms of amyloidogenesis in the pancreatic islets and potential roles in diabetes mellitus. Lab Invest 1992;66:522-535.
7. Johnson KH, O'Brien TD, Betsholtz C, Westermark P. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 1998;321:513-518.
8. Schnider SL, Kohn RR. Glycosylation of human collagen in aging and diabetes mellitus. J Clin Invest 1980;66: 1179-1181.
9. Steiner DF, Ohagi S, Nagamatsu S, Bell GI, Nishi M. Is islet amyloid polypeptide a significant factor in patho genesis or pathophysiology of diabetes? Diabetes 1991;40: 305-309.
10. Röcken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, Roessner A, Goette A. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106:2091-2097.
11. Sasaki N, Takeuchi M, Chowei H, Kikuchi S, Hayashi Y, Nakano N, Ikeda H, Yamagishi S, Kitamoto T, Saito T, Makita Z. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett 2002;326: 117-120.
12. Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P. Alzheimer's disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 1998; 105:439-461.
13. Röcken C, Kientsch-Engel R, Mansfeld S, Stix B, Stubenrauch K, Weigle B, Bühling F, Schwan M, Saeger W. Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis. Amer J Pathol 2003;162:1213-1220.
14. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T. β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243-1252.
15. Hoshii Y, Kawano H, Gondo T, Takahashi M, Ishihara T, Higuchi K, Horiuchi S. Immunohistochemical study with anti-advanced glycation end-products antibody in murine amyloidosis. Pathol Int 1996;46:738-742.
16. Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 1981;211:491-493.
17. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984;101:527-537.
18. Iberg N, Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem 1986;261:13542-13545.
19. Schnider SL, Kohn RR. Effects of age and diabetes mellitus on the solubility and nonenzymatic glycosylation of human skin collagen. J Clin Invest 1981;67:1630-1635.
20. Kohn RR, Cerami A, Monnier VM. Collagen aging in vitro by nonenzymatic glycosylation and browning. Diabetes 1984;33:57-59.
21. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990;87:9010-9014.
22. 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin-1. J Clin Invest 1994;93: 521-528.
23. Vlassara H, Moldawer L, Chan B. Macrophage/monocyte receptor for nonenzymatically glycosylated proteins is upregulated by cachectin/tumor necrosis factor. J Clin Invest 1989;84:1813-1820.
24. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;240;1546-1548.
25. Smith MA, Taneda S, Rickey PL, Miyata S, Yan S-D, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994;91:5710-5714.
26. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Amer J Pathol 1998; 153:1149-1155.
27. Miranova R, Niwa T. Molecular heterogeneity of amyloid β2-microglobulin modification with advanced glycation end products. J Chromotogr B 2001;758:109-115.
28. Nyhlin N, Ando Y, Nagai R, Suhr O, El Sahly M, Terazaki H, Yamashita T, Ando M, Horiuchi S. Advanced glycation end product in familial amyloidotic polyneuropathy (FAP). J Intern Med 2000;247:485-492.
29. Röcken C. Morphologische und tierexperimentelle Untersuchungen zur Prävalenz, Klassifikation und Pathogenese der Amyloidosen. Habilitationsschrift, Otto-von-Guericke-Universität Magdeburg; 1997. pp 1-222.
30. Mihara S, Kawai S, Gondo T, Ishihara T. Intervertebral disc amyloidosis: Histochemical, immunohistochemical and ultrastructural observations. Histopathology 1994;25:415-420.
31. Wullbrand A, Saeger W, Missmahl HP, Voigt C, Linke RP. Amyloid in intervertebral discs of surgery and autopsy material. A new class of amyloid? Virchows Arch A Pathol Anat Histopathol 1990;416:335-341.
32. Ladefoged C, Fedders O, Petersen OF. Amyloid in intervertebral discs: a histopathological investigation of surgical material from 100 consecutive operations on herniated discs. Ann Rheum Dis 1986;45:239-243.
33. Wright JR, Calkins E, Humphrey RL. Potassium permanganate reaction in amyloidosis. A histologic method to assist in differentiating forms of this disease. Lab Invest 1977;36: 274-281.
34. Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glycosylated laminin/type IV collagen. J Biol Chem 1992;267:12404-12407.
35. Röcken C, Schwotzer EB, Linke RP, Saeger W. The classification of amyloid deposits in clinicopathological practice. Histopathology 1996;29:325-335.
36. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962;10:355-364.
37. Missmahl HP. Polarisationsoptische Befunde am Amyloid. In: Bruns G, Zschiesche W, Fritsch S, editors. Fortschritte der Amyloidforschung. Leipzig: Johann Ambrosius Barth; 1966. p 79.
38. Hsu S-M, Raine L, Fanger H. Use of Avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
39. Bywaters EGL, Dorling J. Amyloid deposits in articular cartilage. Ann Rheum Dis 1970;29:294-306.
40. Wagner T, Mohr W. Age distribution of amyloid in the intervertebral disc. Ann Rheum Dis 1984;43:663-664.
41. Takeda T, Sanada H, Ishii M, Matsushita M, Yamamuro T, Shimizu K, Hosokawa M. Age-associated amyloid deposition in surgically-removed herniated intervertebral discs. Arthritis Rheum 1984;27:1063-1065.
42. Mohr W. Amyloid deposits in the periarticular tissue. Zschr Rheumat 1976;35:412-417.
43. Goffin YA, Thoua Y, Potviliege PR. Microdeposition of amyloid in the joints. Ann Rheum Dis 1981;40:27-33.
44. Ladefoged C. Amyloid in osteoarthritic hip joints: deposits in relation to chondromatosis, pyrophosphate, and inflammatory cell infiltrate in the synovial membrane and fibrous capsule. Ann Rheum Dis 1983;42:659-664.
45. Goffin YA, McCrickard EL, Ameryckx JP, Malmendier CL, Hiden M, Cornwell GG, III. Amyloidosis of the joints: evidence that human hip capsules have a unique predisposition for amyloid of the senile systemic type. Appl Pathol 1985; 3:88-95.
46. Ladefoged C. Amyloid in intervertebral discs. A histopathological investigation of intervertebral discs from 30 randomly selected autopsies. Appl Pathol 1985;3:96-104.